



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/695,499	10/28/2003	Vincenzo Scarlato	2300-0363.01	7930

27476 7590 03/29/2005

Chiron Corporation
Intellectual Property - R440
P.O. Box 8097
Emeryville, CA 94662-8097

EXAMINER

GRASER, JENNIFER E

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 03/29/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

41

Office Action Summary	Application No. 10/695,499	Applicant(s) SCARLATO ET AL	
	Examiner Jennifer E. Graser	Art Unit 1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 07 February 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 2,3,8,10-13 and 18-21 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 2,3,8,10-13 and 18-21 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 28 October 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☒ Certified copies of the priority documents have been received in Application No. 09/302,626.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>10/28/03 & 2/7/05</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Election/Restrictions

1. Applicant's election with traverse of Group II, claims 2, 3, 8, 10-13 and 18-21, (SEQ ID NO:3), in the reply filed on 2/7/05 is acknowledged. The traversal is on the ground(s) that SEQ ID Nos: 1 and 5 should be examined along with SEQ ID NO:3. Applicants argue that all three nucleotide sequences are from ORF40. It is argued that it would not place a serious burden on the Examiner to examine all three of the sequences together. This is not found persuasive because the three different nucleic acid sequences are very different structurally and they encode completely different proteins. A search for the nucleic acid sequences would not be coextensive and it would place an undue burden on the Examiner to examine all of the different products together.

The requirement is still deemed proper and is therefore made **FINAL**.

Claim Objections

2. Claims 2, 3, 8, 10-13 and 18-21 are objected to because of the following informalities: they contain non-elected subject matter which should be removed from the claims. Appropriate correction is required.

Specification

3. The disclosure is objected to because of the following informalities: On page 1, line 2, the status of prior application 09/302,626 needs to be updated. The application is now a U.S. Patent.

In the 'Brief Description of the Drawings' which were submitted in the amendments to the specification on 10/28/03, 'Figure 8' should be changed to "Figure 8A-8D' to appropriately reflect the drawings.

Appropriate correction is required.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

5. Claim 13, 8, 12 and 18-20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 13 is vague and indefinite because it is unclear what is encompassed by the term "high stringency conditions" and hybridization conditions can vary considerably. A number of parameters govern the stringency of the hybridization including the hybridization temperature, hybridization time, washing temperature, washing time, formamide concentration, detergent concentration and salt concentration. Changes in these parameters will affect the specificity of the binding. Thus, in order to ascertain the metes and bounds of the patent protection, the skilled artisan would require a knowledge of these specific parameters. The claim does not clearly and unambiguously set forth the appropriate reaction conditions. The rejection may be overcome by clearly setting forth the reaction conditions encompassed by a stringent hybridization, as supported by the disclosure. While the specification can be used to provide definitive support, the claims are not read in a vacuum. Rather, the claim must be definite and

Art Unit: 1645

complete in and of itself. Limitations from the specification will not be read into the claims. The claims as they stand are incomplete and fail to provide adequate structural properties to allow for one to identify what is being claimed. The specific hybridization conditions are critical limitations.

Claims 8, 12 and 18-20 recite isolated nucleic acid sequences with a percent identity to a given sequence, but no function is provided for the claimed nucleic acid sequence. It is unclear what function these variants would serve. The claims can be clarified by an amendment, provided there is written support in the specification, stating that the nucleic acid sequence can detect *N.meningitidis* through the high stringency conditions which are to be incorporated in claim 13.

Claim Rejections - 35 USC § 112

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 8, 12, 13 and 18-21 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for "an isolated nucleic acid sequence comprising SEQ ID NO:3", "an isolated nucleic acid sequence which encodes a protein comprising the amino acid sequence set forth in SEQ ID NO:4", and isolated nucleic acid molecules which hybridize to these nucleic acid molecule under high stringency conditions (provided they are specifically recited in the claim), does not reasonably provide enablement for isolated nucleic acid sequences which have 50% or greater identity to an isolated nucleic acid sequence set forth in SEQ ID NO:3, isolated nucleic

Art Unit: 1645

acid sequences which encode 10-mer fragments or isolated nucleic acid sequences which are 80-95% identical to SEQ ID NO:3 with no stated function. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

The breadth of the instant claims is drawn to polynucleotides which are not specified in the sequence disclosure. The specification states that substitutions, additions, or deletions may be made to the defined sequences; however, the specification provides no guidance as to what nucleic acids may be changed without causing a detrimental effect to the adhesion and penetration protein to be produced. Further, it is unpredictable as to which amino acids could be removed and which could be added. While it is known that many amino acid substitutions are possible in any given protein, the position within the protein's sequence where amino acid substitutions can be made with a reasonable expectation of success are limited. Other positions are critical to the protein's structure/function relationship, e.g., such as various positions or regions directly involved in binding, catalysis in providing the correct three-dimensional spatial orientation of binding and catalytic sites. These regions can tolerate only very little or no substitutions. To start with the DNA sequence first, this requires even more work on the part of the skilled artisan.

The instant claims are drawn to nucleic acids comprising a sequence with a given percent similarity to a nucleic acid which encodes a protein. Selective point mutation to one key residue could eliminate the function of the polypeptide. It could

eliminate its adhesion and penetration properties. If the range of decreased binding ability after single point mutation of a protein antigen varies, one could expect point mutations in the protein antigen to cause varying degrees of loss of protection/function, depending on the relative importance to the binding interaction of the altered residue. Alternatively, the combined effects of multiple changes in an antigenic determinant could again result in loss of function. A protein having multiple antigenic sites, multiple point mutations, or accumulated point mutations at key residues could create a new antigen that is precipitously or progressively unrecognizable by any of the antibodies in the polyclonal pool. As stated above, Applicants have not shown which nucleotides may be changed without causing a detrimental effect to the protein in which it encodes. The claims allow for as great as 50% variation. This is a huge variation allowing for many gaps, insertions, substitutions and deletions. It is unclear that a sequence with this much variation would even have the ability to detect *N.meningitidis* in a hybridization assay. Applicants have provided no guidance to enable one of ordinary skill in the art how to determine, without undue experimentation, the effects of different nucleotide substitutions and the nature and extent of the changes that can be made. It is expensive and time consuming to make amino acid substitutions at more than one position, in a particular region of the protein, in view of the many fold possibilities for change in structure and the uncertainty as to what utility will be possessed. See Mikayama et al. (Nov.1993. Proc.Natl.Acad.Sci. USA, vol. 90 : 10056-10060) which teaches that the three-dimensional structure of molecules is important for their biological function and even a single amino acid difference may account for markedly different

Art Unit: 1645

biological activities. Rudinger et al. (June 1976. Peptide Hormones. Biol.Council. pages 5-7) also teaches that amino acids owe their 'significance' to their inclusion in a pattern which is directly involved in recognition by, and binding to, the receptor and the significance of the particular amino acids and sequences for different amino acids cannot be predicted *a priori*, but must be determined from case to case by painstaking experimental study. The specification also fails to teach the location of immunogenic epitopes. Therefore, it would take undue experimentation for one of skill in the art to determine which 30 nucleotides would encode a 10-mer immunogenic fragment. Given the lack of guidance contained in the specification regarding acceptable nucleotide substitutions, additions or deletions, one of skill in the art could not make or use the broadly claimed invention without undue experimentation.

Claim Rejections - 35 USC § 102

8. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

9. Claims 2, 3, 8, 10-13 and 18-21 are rejected under 35 U.S.C. 102(e) as being anticipated by Peak et al (US Patent No. 6,197,312). Peak et al. has priority back to 12/12/97.

Peak et al disclose an isolated nucleic acid sequence which is 99.8% identical to Applicant's SEQ ID NO:3. See attached sequence alignment. Peak et al also teach a

Art Unit: 1645

protein which comprises an amino acid sequence 100% identical to Applicants' SEQ ID

NO:4. Nucleotide sequences which hybridize to SEQ ID NO:3 are also taught.

Fragments from SEQ ID NO:4 and the nucleic acids that encode them are also taught.

Status of Claims:

10. No claims are allowed.

11. Correspondence regarding this application should be directed to Group Art Unit 1645. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Remsen. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1645 Fax number is 571-273-8300 which is able to receive transmissions 24 hours/day, 7 days/week.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer E. Graser whose telephone number is (571) 272-0858. The examiner can normally be reached on Monday-Friday from 7:00 AM-4:30 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached on (571) 272-0864.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-0500.


Jennifer Graser
Primary Examiner
Art Unit 1645

3/17/05